Patents by Inventor Christopher F. O'Brien

Christopher F. O'Brien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200338066
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
    Type: Application
    Filed: October 10, 2017
    Publication date: October 29, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
    Publication number: 20200276184
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Application
    Filed: September 18, 2018
    Publication date: September 3, 2020
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O`Brien
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200268724
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200268743
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200268725
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200268744
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient has mild, moderate, or severe hepatic impairment.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200268745
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
    Type: Application
    Filed: May 11, 2020
    Publication date: August 27, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200230127
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
    Type: Application
    Filed: October 10, 2017
    Publication date: July 23, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • USE OF VALBENAZINE FOR TREATING LEVODOPA-INDUCED DYSKINESIA
    Publication number: 20200179352
    Abstract: Provided herein are methods for treating levodopa-induced dyskinesia by administering to a subject (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 11, 2020
    Inventor: Christopher F. O`Brien
  • TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS
    Publication number: 20200101063
    Abstract: Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)?-HTBZ) is used in the methods described herein for treating a subject in need thereof.
    Type: Application
    Filed: December 3, 2019
    Publication date: April 2, 2020
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20200093808
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
    Type: Application
    Filed: October 10, 2017
    Publication date: March 26, 2020
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
    Publication number: 20200078352
    Abstract: Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 12, 2020
    Inventor: Christopher F. O`Brien
  • Methods for the Administration of Certain VMAT2 Inhibitors
    Publication number: 20190381016
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
    Type: Application
    Filed: October 10, 2017
    Publication date: December 19, 2019
    Inventors: Christopher F. O`Brien, Haig P. Bozigian
  • VMAT2 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES OR DISORDERS
    Publication number: 20190015396
    Abstract: Methods are provided herein for treating agitation in a subject who has Alzheimer's disease comprising administering a VMAT2 inhibitor to a subject in need thereof. VMAT2 inhibitors useful in the methods provided herein include tetrabenazine and (S)-2-Amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester.
    Type: Application
    Filed: June 23, 2016
    Publication date: January 17, 2019
    Inventor: Christopher F. O'BRIEN
  • TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS
    Publication number: 20170071932
    Abstract: Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)?-HTBZ) is used in the methods described herein for treating a subject in need thereof.
    Type: Application
    Filed: May 6, 2015
    Publication date: March 16, 2017
    Inventor: Christopher F. O'Brien